Prof Robert Orlowski speaks to ecancer about the IMROZ study, presented at ASCO 2024, with further data published at ASH 2024.

This study compares isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) to bortezomib, lenalidomide, and dexamethasone (VRd) for transplant-ineligible patients with newly diagnosed multiple myeloma.

Dr Orlowski notes that isatuximab, bortezomib, lenalidomide, and dexamethasone significantly improves progression-free survival and response rates, especially for patients ineligible for transplants.

He added that the trial is unique in its focus on this therapy and highlights the importance of optimal upfront treatment.

Dr Orlowski concludes by covering health-related quality of life data from ASH and comments on the impact of the study from a US perspective.